The global papaverine hydrochloride injection market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). The increase in cases of heart-related disease, growing aging population, and erectile dysfunction are the major factors that are expected to accelerate the market growth during the forecast period. Papaverine Hydrochloride appears as white crystals or white crystalline powder. It is labeled with USP and is not approved by the FDA. This injection is available in packages of 30 mL and in 120 mL and is used for treating spasms of smooth muscle, angina pectoris, peripheral and pulmonary embolism, peripheral vascular disease, or certain cerebral antispastic states, visceral spasm, and erectile dysfunction.
According to the Massachusetts Male Aging Study, the prevalence of erectile dysfunction (ED) is reported as 52% in the US. The study revealed that ED is progressively dominant with age. Approximately 40% of men are affected at age 40. Furthermore, according to the Massachusetts study data, there will be approximately 17,781 new cases of ED in Massachusetts and 617,715 in the US annually. This, in turn, is expected to further accelerate the demand for papaverine which is injected into the penis as it increases the blood flow to the penis, resulting in an erection.
Market Coverage
Competitive Landscape: Sandoz International GmbH, and Chengdu Brilliant Pharmaceutical Group, among others.
Key questions addressed by the report
o Recovery Timeline
o Deviation from pre-COVID forecast
o Most affected region and segment
Global Papaverine Hydrochloride Injection Market Report by Segment
By Type
• 30 mg/mL,
• 120 mg/10 mL
By Application
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
Global Papaverine Hydrochloride Injection Market by Region
North America
Europe
Asia-Pacific
Rest of the World